ABV-1501 / ABVC BioPharma - LARVOL DELTA

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Aug 2027 ➔ Aug 2028 | Trial primary completion date: Apr 2027 ➔ Apr 2028

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Aug 2025 ➔ Aug 2027 | Trial primary completion date: Apr 2025 ➔ Apr 2027

Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M (GlobeNewswire) - "ABVC BioPharma, Inc...announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the 'Licensed Products')....Under the proposed agreement, ABVC would grant OncoX an exclusive global rights license to develop and commercialize the Licensed Products within the Field of Use. ABVC would also grant OncoX the right to sublicense to a third party, pre-agreed by ABVC....The terms discussed or agreed upon are conditional and not final until a formal Definitive Agreement is executed by all parties involved."

Licensing / partnership • Breast Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Feb 2025 ➔ Aug 2025 | Trial primary completion date: Oct 2024 ➔ Apr 2025

Metastases • Surgery • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

ABVC BioPharma Provides 2023 Pipeline Update (GlobeNewswire) - "While the company’s additional oncology medicines have yet to be determined, ABVC anticipates clinical studies for ABV-1519 for non-small cell lung cancer and ABV-1501 for triple negative breast cancer will be initiated in Q3 2023. The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023. In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States."

New P2 trial • New trial • Breast Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. (clinicaltrials.gov) - P1/2 | N=44 | Not yet recruiting | Sponsor: BioLite, Inc. | Trial completion date: Feb 2024 ➔ Feb 2025 | Trial primary completion date: Oct 2023 ➔ Oct 2024

Metastases • Surgery • Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2 • PGR

ABVC Provides Oncology Pipeline Updates (GlobeNewswire) - "ABVC BioPharma, Inc...today provided an update on its development of oncology medicines for the treatment pancreatic cancer (ABV-1703), non-small cell lung cancer (ABV-1519), triple negative breast cancer (ABV-1501) and myelodysplastic syndrome (ABV-1702). The Company expects to initiate the first Phase II clinical trials for ABV-1703 in the second quarter of 2023 by Dr. Andrew E. Hendifar at the Cedars-Sinai Medical Center in Los Angeles, California....While the sites and principal investigators for the Company’s additional oncology medicines have yet to be determined, ABVC anticipates clinical studies for ABV-1519 for non-small cell lung cancer and ABV-1501 for triple negative breast cancer will be initiated in Q3 2023. The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023. The Company plans to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States."

New P2 trial • New trial • Non-US regulatory • Breast Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Triple Negative Breast Cancer